Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. reports news about its consumer telehealth platform, which connects customers with providers and offers treatment options across areas such as sexual health, hair loss, skin care, mental health and weight loss. Company updates commonly cover prescription access, FDA-approved GLP-1 weight loss medications, platform memberships, subscriber benefits and health-and-wellness partner programs.
Recurring developments also include operating and financial results, conference participation, board and executive appointments, shareholder voting matters, governance updates and clinical or regulatory disclosures tied to products available through the Hims and Hers platform.
Hims & Hers (NYSE: HIMS) launched Hims & Hers Benefits on March 10, 2026, a subscriber program offering partner discounts on whole‑body health and recovery products. Initial partners include Prenuvo (radiation‑free whole body MRI) with $400 off scans and Eight Sleep (adaptive beds) with up to $350 off Pod 5 series.
The company says 100% of negotiated savings are passed to active subscribers and deals are available immediately; full terms at hims.com/benefits and forhers.com/benefits.
Hims & Hers (NYSE: HIMS) announced a strategic shift for its US weight loss business, aligning US and global models and collaborating with Novo Nordisk to expand access to FDA-approved GLP-1 treatments.
The company will promote branded FDA-approved GLP-1s, offer limited compounded semaglutide for select clinical cases, and add Ozempic and Wegovy formulations to its platform later this month.
Hims & Hers (NYSE: HIMS) reported 2025 revenue of $2.35 billion, up 59% year-over-year, net income of $128.4 million, and Adjusted EBITDA of $318.0 million. Subscribers exceeded 2.5 million (up 13%). The company provided 2026 guidance: $2.7B–$2.9B revenue and $300M–$375M Adjusted EBITDA.
Q4 revenue was $617.8M (+28% YoY), gross margin declined to 72%, and full-year free cash flow was $57.4M. Guidance excludes the proposed Eucalyptus acquisition and assumes continued access to compounded semaglutide.
Hims & Hers (NYSE: HIMS) agreed to acquire Eucalyptus to accelerate international expansion and create a diversified global consumer health platform.
The transaction is valued at up to $1.15 billion USD, with approximately $240 million USD payable in cash at closing and remaining consideration in deferred and earnout payments through early 2029. Hims & Hers expects close in mid-2026.
Hims & Hers (NYSE: HIMS) expanded its weight loss portfolio by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy, offered needle-free and formulated for digestion and absorption. Intro pricing starts at $49 for month one with a 5-month plan; standard pricing is $99/month thereafter. The company doubled facility footprint in 2025 to over 1 million sq ft, citing integrated pharmacy, lab, and R&D capacity. Hims & Hers says APIs for compounded products come from FDA-registered facilities and notes compounded drugs are not FDA-evaluated.
Hims & Hers (NYSE: HIMS) launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a blood-based multi-cancer early detection (MCED) test that screens for a signal across 50+ types of cancer and predicts likely tissue of origin.
Customers can add the Galleri test to existing Labs plans with a $250 discount off Galleri list price, enabling annual proactive screening alongside recommended tests.
Hims & Hers (NYSE: HIMS) will report fourth quarter and full year 2025 financial results after market close on Monday, February 23, 2026. A live conference call is scheduled for 5:00 p.m. ET, with dial-in details and a live audio webcast at https://investors.hims.com, archived for one year.
Company management will also participate in the Morgan Stanley Technology, Media & Telecom Conference on March 2, 2026 in San Francisco.
Hims & Hers (NYSE: HIMS) returns to the Big Game with a national spot titled “Rich People Live Longer”, airing February 8, 2026. The ad argues that proactive, preventive care should be accessible to all and cites research that the top 1% live seven years longer than the bottom 50%.
The campaign highlights Hims & Hers’ platform features, including Labs testing (routine markers and an early cancer detection test), microdose metabolic treatments, and clinician-guided hormone care. Voice talent includes artist Common to emphasize health equity and awareness.
Hims & Hers (HIMS) launched its Hers platform in the UK on December 10, 2025, extending its comprehensive Weight Loss Programme to eligible British customers.
The digital programme pairs GMC‑registered clinicians with personalised care, 24/7 support, and treatment options that may include branded GLP‑1s (Mounjaro, Wegovy) and oral Orlos after a clinically robust intake assessment. The offering emphasises long‑term lifestyle support across nutrition, movement, and sleep and positions Hers as a women‑focused, telehealth route complementary to NHS services.
Hims & Hers (NYSE: HIMS) announced it is now serving customers in Canada following its acquisition of Livewell, a Canadian digital weight-loss platform. The company said the expansion will accelerate a Canadian launch of its comprehensive weight loss program next year, timed with the anticipated first availability of generic semaglutide. Hims & Hers named Austin Kouri as General Manager of Canada and announced Dr. Sandy Van as Canada chief medical advisor, with Livewell co-founders joining the Canadian leadership team.
The move emphasizes localized leadership, accessible digital care, and planned specialty expansion in Canada.